Literature DB >> 20346966

Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents.

Neil E Paterson1, Allison Fedolak, Berend Olivier, Taleen Hanania, Afshin Ghavami, Barbara Caldarone.   

Abstract

UNLABELLED: The present studies assessed the potential abuse liability and likely mechanism(s) of action of the wake-promoting agent modafinil.
METHODS: Experiments assessed the locomotor sensitization (LS) and discriminative stimulus (DS) properties of modafinil in mouse and rat, respectively. Comparative data were generated with a range of psychostimulants and monoamine reuptake inhibitors.
RESULTS: Repeated administration of d-amphetamine and cocaine, psychostimulants with high abuse liability, resulted in the induction and expression of LS in mice. Bupropion and caffeine, two psychostimulants not abused in humans, were not associated with LS. GBR12909 induced LS during repeated exposure, but there was no evidence of expression of LS after acute challenge following withdrawal. In contrast, repeated administration of modafinil resulted in the expression, but not induction, of LS. d-amphetamine, but not the mu-opioid agonist morphine or the nAChR agonist nicotine, fully substituted for the cocaine DS in rats. The selective dopamine transporter (DAT) inhibitor GBR12909 fully substituted, the preferential norepinephrine transporter (NET) inhibitor desipramine partially substituted, and the selective serotonin reuptake inhibitor citalopram failed to substitute for cocaine. Modafinil fully substituted for cocaine, similar to the mixed DAT/NET inhibitor bupropion.
CONCLUSIONS: Two preclinical assays indicated potential abuse liability of modafinil; drug discrimination studies suggest DAT blockade by modafinil is a likely mechanism of action in vivo. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20346966      PMCID: PMC2880855          DOI: 10.1016/j.pbb.2010.03.006

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  63 in total

1.  MK801 attenuates behavioural adaptation to chronic nicotine administration in rats.

Authors:  M Shoaib; I P Stolerman
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

2.  Modafinil binds to the dopamine uptake carrier site with low affinity.

Authors:  E Mignot; S Nishino; C Guilleminault; W C Dement
Journal:  Sleep       Date:  1994-08       Impact factor: 5.849

3.  Acute behavioral and physiological effects of modafinil in drug abusers.

Authors:  C R Rush; T H Kelly; L R Hays; R W Baker; A F Wooten
Journal:  Behav Pharmacol       Date:  2002-03       Impact factor: 2.293

4.  Dopaminergic role in stimulant-induced wakefulness.

Authors:  J P Wisor; S Nishino; I Sora; G H Uhl; E Mignot; D M Edgar
Journal:  J Neurosci       Date:  2001-03-01       Impact factor: 6.167

5.  Asymmetric generalization between the discriminative stimulus effects of nicotine and cocaine.

Authors:  R I Desai; D J Barber; P Terry
Journal:  Behav Pharmacol       Date:  1999-11       Impact factor: 2.293

6.  Modification of behavioral effects of cocaine by selective serotonin and dopamine uptake inhibitors in squirrel monkeys.

Authors:  R D Spealman
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Smoked cocaine self-administration is decreased by modafinil.

Authors:  Carl L Hart; Margaret Haney; Suzanne K Vosburg; Eric Rubin; Richard W Foltin
Journal:  Neuropsychopharmacology       Date:  2007-06-13       Impact factor: 7.853

8.  Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis.

Authors:  K Fuxe; A M Janson; L Rosén; U B Finnman; S Tanganelli; M Morari; M Goldstein; L F Agnati
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

9.  A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder.

Authors:  Manijeh Kahbazi; Aboulfazl Ghoreishi; Fatemeh Rahiminejad; Mohammad-Reza Mohammadi; Abbas Kamalipour; Shahin Akhondzadeh
Journal:  Psychiatry Res       Date:  2009-05-12       Impact factor: 3.222

10.  Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs.

Authors:  R F Suckow; T M Smith; A S Perumal; T B Cooper
Journal:  Drug Metab Dispos       Date:  1986 Nov-Dec       Impact factor: 3.922

View more
  20 in total

Review 1.  Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Authors:  Colin N Haile; James J Mahoney; Thomas F Newton; Richard De La Garza
Journal:  Pharmacol Ther       Date:  2012-01-31       Impact factor: 12.310

2.  R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse.

Authors:  Claus J Loland; Maddalena Mereu; Oluyomi M Okunola; Jianjing Cao; Thomas E Prisinzano; Sonia Mazier; Theresa Kopajtic; Lei Shi; Jonathan L Katz; Gianluigi Tanda; Amy Hauck Newman
Journal:  Biol Psychiatry       Date:  2012-04-25       Impact factor: 13.382

3.  Chronic modafinil effects on drug-seeking following methamphetamine self-administration in rats.

Authors:  Carmela M Reichel; Ronald E See
Journal:  Int J Neuropsychopharmacol       Date:  2011-06-28       Impact factor: 5.176

4.  Acute behavioural effects of bupropion and naltrexone, alone and in combination, in non-deprived male rats presented with palatable mash.

Authors:  F L Wright; R J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  2013-03-01       Impact factor: 4.530

Review 5.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

6.  The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.

Authors:  Barbara J Caldarone; Neil E Paterson; Jia Zhou; Daniela Brunner; Alan P Kozikowski; Koen G C Westphal; Gerdien A H Korte-Bouws; Jolanda Prins; S Mechiel Korte; Berend Olivier; Afshin Ghavami
Journal:  J Pharmacol Exp Ther       Date:  2010-09-23       Impact factor: 4.030

7.  Dopaminergic mediation of the discriminative stimulus functions of modafinil in rats.

Authors:  Amanda J Quisenberry; Lisa E Baker
Journal:  Psychopharmacology (Berl)       Date:  2015-09-15       Impact factor: 4.530

8.  Preclinical evaluation of the abuse potential of Pitolisant, a histamine H₃ receptor inverse agonist/antagonist compared with Modafinil.

Authors:  M Uguen; D Perrin; S Belliard; X Ligneau; P M Beardsley; J M Lecomte; J C Schwartz
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

9.  Interactions between modafinil and cocaine during the induction of conditioned place preference and locomotor sensitization in mice: implications for addiction.

Authors:  Tristan Shuman; Denise J Cai; Jennifer R Sage; Stephan G Anagnostaras
Journal:  Behav Brain Res       Date:  2012-08-03       Impact factor: 3.332

10.  The unique psychostimulant profile of (±)-modafinil: investigation of behavioral and neurochemical effects in mice.

Authors:  Maddalena Mereu; Lauren E Chun; Thomas E Prisinzano; Amy H Newman; Jonathan L Katz; Gianluigi Tanda
Journal:  Eur J Neurosci       Date:  2016-09-11       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.